Risk-Guided Screening for Atrial Fibrillation Using Electronic Health Records

R Ramesh Nadarajah J Jianhua Wu A Ali Wahab C Catherine Reynolds M Mohammad Haris T Tobin Joseph K Keerthenan Raveendra B Ben Hurdus K Khalid Kazi S Sheena Bennett C Chris Hayward B Ben Mercer J Jing Kang (Translational Immunology, Genentech) C Chenyi Gao (Wolfson Institute of Population Health, Queen Mary, University of London, London, United Kingdom (J.W., C.G.).) Y Yoko M. Nakao K Koji Kawakami C Carlin Chang (Department of Medicine, University of Hong Kong, Hong Kong SAR, China. (C.C.)) A Abraham Wai (Department of Emergency Medicine, University of Hong Kong, Hong Kong SAR, China. (A.W.)) J Jiandong Zhou G Gary Tse T Talish Razi Benita (Community Medical Services Division, Clalit Healthcare Services, Tel Aviv, Israel (T.R.B., R.A., M.H., D.Z.).) L Lior Rokach R Ronen Arbel (Community Medical Services Division, Clalit Healthcare Services, Tel Aviv, Israel (T.R.B., R.A., M.H., D.Z.).) M Moti Haim (Community Medical Services Division, Clalit Healthcare Services, Tel Aviv, Israel (T.R.B., R.A., M.H., D.Z.).) D Doron Zahger (Community Medical Services Division, Clalit Healthcare Services, Tel Aviv, Israel (T.R.B., R.A., M.H., D.Z.).) D Dina Labib (Department of Cardiac Sciences and Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada (D.L., J.F., J.A.W.).) J Jacqueline Flewitt (Department of Cardiac Sciences and Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada (D.L., J.F., J.A.W.).) J James A. White (Department of Cardiac Sciences and Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada (D.L., J.F., J.A.W.).) K Konsta Teppo (Heart Center, Turku University Hospital and University of Turku, Turku, Finland. (K.T., K.E.J.A.)) M Mika Lehto (Jorvi Hospital, Department of Internal Medicine (M. Lehto), HUS Helsinki University Hospital and University of Helsinki, Helsinki, Finland.) V Ville Langén (Division of Medicine, Turku University Hospital and University of Turku, Turku, Finland. (V.L.)) A Aleksi K. Winstén K K.E. Juhani Airaksinen (Heart Center, Turku University Hospital and University of Turku, Turku, Finland. (K.T., K.E.J.A.)) J Jari Haukka (Department of Public Health, University of Helsinki, Helsinki, Finland (J. Haukka).) O Olli Halminen (Departments of Health and Social Management, University of Eastern Finland, Finland. (O.H.)) J Jukka Putaala (Department of Neurology, University of Helsinki and Helsinki University Hospital, Helsinki) J Juha Hartikainen M Miika Linna (Health and Social Management, University of Eastern Finland, Finland.(M. Linna)) B Ben Freedman (Heart Research Institute, Sydney Medical School, Charles Perkins Center, and Cardiology Department, The University of Sydney, Sydney, NSW, Australia (B.F.).) E Emma Svennberg (Karolinska Institutet, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden (E.S.).) A A. John Camm (Cardiology Clinical Academic Group, Molecular and Clinical Sciences Institute, City St. George’s University of London, London) G Gregory Y. H. Lip C Chris P. Gale

Abstract

BACKGROUND: Screening for atrial fibrillation (AF) on the basis of AF risk may be more effective. We aimed to develop, externally validate, and prospectively test a machine learning prediction model using electronic health records (EHRs) to guide AF screening. METHODS: We developed and validated a random forest prediction model for new AF within 6 months, using age, sex, and 10 comorbidities (Future Innovations in Novel Detection of Atrial Fibrillation [FIND-AF] 2.0) in EHRs in the United Kingdom (n=2 081 139), Japan (n=7 795 244), Israel (n=2 166 795), Canada (n=627 919), and China (n=149 145). We conducted a prospective study where participants ≥30 years old without AF and with a CHA 2 DS 2 -VASc score ≥2 in men and ≥3 in women, stratified by FIND-AF 2.0 into high and low risk, undertook 4 ECG recordings per day for 3 weeks using a handheld ECG recorder, with a primary outcome of newly diagnosed AF. We estimated stroke risk associated with nonanticoagulated AF in patients with high FIND-AF 2.0 risk in the FinACAF (Finnish Anticoagulation in Atrial Fibrillation) registry of patients with AF (n=229 565). RESULTS: FIND-AF 2.0 was applicable to all EHRs and showed good to excellent prediction performance (United Kingdom: area under the receiver operating characteristic curve [AUROC], 0.819 [95% CI, 0.809–0.829]; Israel: AUROC, 0.835 [95% CI, 0.828–0.842]; Japan: AUROC, 0.751 [95% CI, 0.745–0.757]; Canada: AUROC, 0.747 [95% CI, 0.741–0.753]; China: AUROC, 0.753 [95% CI, 0.725–0.771]), with AUROC>0.7 in men and women in all cohorts, and improved performance compared with CHA 2 DS 2 -VASc and C 2 HEST. Of 1923 participants from 15 sites in the prospective study (mean age, 70.2 [SD 9.4] years), with a mean of 74.8 (SD, 19.4) ECG recordings, AF was diagnosed in 5 of 902 (0.6%) with low FIND-AF 2.0 risk and 46 of 1021 (4.5%) with high FIND-AF 2.0 risk (odds ratio, 8.46 [95% CI, 3.35–21.40], P <0.001). Median AF burden among high FIND-AF 2.0 risk–detected cases was 33.4% (interquartile range, 5.1%–91.6%), and 96.1% initiated oral anticoagulants. In the FinACAF registry, the rate of ischemic stroke for patients with high FIND-AF 2.0 risk, AF, and no anticoagulants was 6.0 events per 100 patient-years. CONCLUSIONS: The EHR-based machine learning model, FIND-AF 2.0, identifies a high-risk subpopulation for AF diagnosis among patients at elevated risk of stroke and could enable scalable, EHR-driven, risk-guided AF screening.

Article Details

Journal Circulation
Volume / Issue Vol. 1, Issue 1
Published July 28, 2026
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (43)

R

Ramesh Nadarajah

J

Jianhua Wu

A

Ali Wahab

C

Catherine Reynolds

M

Mohammad Haris

T

Tobin Joseph

K

Keerthenan Raveendra

B

Ben Hurdus

K

Khalid Kazi

S

Sheena Bennett

C

Chris Hayward

B

Ben Mercer

J

Jing Kang

Translational Immunology, Genentech

C

Chenyi Gao

Wolfson Institute of Population Health, Queen Mary, University of London, London, United Kingdom (J.W., C.G.).

Y

Yoko M. Nakao

K

Koji Kawakami

C

Carlin Chang

Department of Medicine, University of Hong Kong, Hong Kong SAR, China. (C.C.)

A

Abraham Wai

Department of Emergency Medicine, University of Hong Kong, Hong Kong SAR, China. (A.W.)

J

Jiandong Zhou

G

Gary Tse

T

Talish Razi Benita

Community Medical Services Division, Clalit Healthcare Services, Tel Aviv, Israel (T.R.B., R.A., M.H., D.Z.).

L

Lior Rokach

R

Ronen Arbel

Community Medical Services Division, Clalit Healthcare Services, Tel Aviv, Israel (T.R.B., R.A., M.H., D.Z.).

M

Moti Haim

Community Medical Services Division, Clalit Healthcare Services, Tel Aviv, Israel (T.R.B., R.A., M.H., D.Z.).

D

Doron Zahger

Community Medical Services Division, Clalit Healthcare Services, Tel Aviv, Israel (T.R.B., R.A., M.H., D.Z.).

D

Dina Labib

Department of Cardiac Sciences and Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada (D.L., J.F., J.A.W.).

J

Jacqueline Flewitt

Department of Cardiac Sciences and Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada (D.L., J.F., J.A.W.).

J

James A. White

Department of Cardiac Sciences and Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada (D.L., J.F., J.A.W.).

K

Konsta Teppo

Heart Center, Turku University Hospital and University of Turku, Turku, Finland. (K.T., K.E.J.A.)

M

Mika Lehto

Jorvi Hospital, Department of Internal Medicine (M. Lehto), HUS Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

V

Ville Langén

Division of Medicine, Turku University Hospital and University of Turku, Turku, Finland. (V.L.)

A

Aleksi K. Winstén

K

K.E. Juhani Airaksinen

Heart Center, Turku University Hospital and University of Turku, Turku, Finland. (K.T., K.E.J.A.)

J

Jari Haukka

Department of Public Health, University of Helsinki, Helsinki, Finland (J. Haukka).

O

Olli Halminen

Departments of Health and Social Management, University of Eastern Finland, Finland. (O.H.)

J

Jukka Putaala

Department of Neurology, University of Helsinki and Helsinki University Hospital, Helsinki

J

Juha Hartikainen

M

Miika Linna

Health and Social Management, University of Eastern Finland, Finland.(M. Linna)

B

Ben Freedman

Heart Research Institute, Sydney Medical School, Charles Perkins Center, and Cardiology Department, The University of Sydney, Sydney, NSW, Australia (B.F.).

E

Emma Svennberg

Karolinska Institutet, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden (E.S.).

A

A. John Camm

Cardiology Clinical Academic Group, Molecular and Clinical Sciences Institute, City St. George’s University of London, London

G

Gregory Y. H. Lip

C

Chris P. Gale